MRNA Jun 2024 60.000 call
OPR - OPR Delayed Price. Currency in USD
Add to watchlist
As of 11:21AM EDT. Market open.
Loading interactive chart...
- ACCESSWIRE
Moderna Announces Positive Phase 3 Efficacy Data for mRNA-1283, the Company’s Next Generation COVID-19 Vaccine
mRNA-1283 met its primary vaccine efficacy endpoint in a Phase 3 trial, demonstrating non-inferior vaccine efficacy against COVID-19 compared to Spikevax® in participants 12 years of age and older Higher efficacy was observed in mRNA-1283 compared ...
- Investor's Business Daily
Is Moderna Stock A Buy After Its Second-Ever Product Snags FDA Approval?
Moderna stock is trading sideways despite a bevy of news, including FDA approval for its RSV vaccine. Is MRNA stock a buy right now?
- Yahoo Finance
Moderna president: Company outlook 'stabilizing' thanks to new flu-COVID vaccine data
Moderna revealed its combination flu/COVID vaccine performed better than the two shots independently.
© 2024 Yahoo. All rights reserved.